Enhancement of Humoral and Cellular Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 by a Third Dose of BNT162b2 Vaccine in Japanese Healthcare Workers-Reference-Cited by-同舟云学术

Enhancement of Humoral and Cellular Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 by a Third Dose of BNT162b2 Vaccine in Japanese Healthcare Workers

Published:2022-08-18 Issue:2 Volume:227 Page:221-225
ISSN:0022-1899
Container-title:The Journal of Infectious Diseases
language:en
Short-container-title:

Author:

Miyakawa Kei¹^ORCID,Kato Hideaki²^ORCID,Ohtake Norihisa³⁴^ORCID,Jeremiah Sundararaj Stanleyraj¹^ORCID,Ryo Akihide¹^ORCID

Affiliation:

1. Department of Microbiology, Yokohama City University School of Medicine , Kanagawa , Japan

2. Infection Prevention and Control Department, Yokohama City University Hospital , Kanagawa , Japan

3. Advanced Medical Research Center, Yokohama City University , Kanagawa , Japan

4. Bioscience Division, Research and Development Department, Tosoh Corporation, Tokyo Research Center , Kanagawa , Japan

Abstract

Abstract The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has raised concerns regarding vaccine effectiveness. We investigated humoral and cellular immune responses against SARS-CoV-2 in healthcare workers before and after a third (booster) dose of the BNT162b2 messenger RNA vaccine. It significantly enhanced both humoral and cellular immunity in previously uninfected individuals. However, cellular immunity was not enhanced in previously infected persons, suggesting that 3 antigenic stimuli by vaccination or natural infection reached a plateau of cellular immunity. Even with reinforced immunity to SARS-CoV-2, we confirmed several postbooster breakthrough cases caused by the Omicron variant.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Immunology and Allergy

Link

https://academic.oup.com/jid/advance-article-pdf/doi/10.1093/infdis/jiac344/47016340/jiac344.pdf

Reference15 articles.

1. SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection;Cele;medRxiv [Preprint]. Posted online 17 December,2021

2. Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies;Wilhelm;medRxiv [Preprint]. Posted online 13 December,2021

3. SARS-CoV-2 B.1.1.529 variant (Omicron) evades neutralization by sera from vaccinated and convalescent individuals;Rössler;medRxiv [Preprint]. Posted online 11 December,2021

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Differential Severe Acute Respiratory Syndrome Coronavirus 2–Specific Humoral Response in Inactivated Virus–Vaccinated, Convalescent, and Breakthrough-Infected Subjects;The Journal of Infectious Diseases;2023-08-12

2. Booster Dose of SARS-CoV-2 mRNA Vaccine in Kidney Transplanted Patients Induces Wuhan-Hu-1 Specific Neutralizing Antibodies and T Cell Activation but Lower Response against Omicron Variant;Viruses;2023-05-09

3. SARS-CoV-2 Seroprevalence among Canadian Blood Donors: The Advance of Omicron;Viruses;2022-10-25